{
  "id": 21221627,
  "title": "Vertex’s executive chairman: Here’s how we got our drug-trial success rate over 70% when the industry’s is 10% to 20%",
  "url": "https://urgent.news/2026/11/22/vertexs-executive-chairman-heres-how-we-got-our-drug-trial-success",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-22T13:30:00.000Z",
  "source": {
    "name": "Fortune",
    "slug": "fortune",
    "url": "https://fortune.com/2026/11/22/vertex-leiden-rd-success-rate-fewer-smarter-bets-innovation/"
  },
  "original_language": "en",
  "account": "Vertex Pharmaceuticals has achieved a drug-trial success rate of over 70%, significantly higher than the industry average of 10% to 20%. The company's journey began in 2009, when it joined a company that had invested heavily in R&D across 20 different programs but only produced a single breakthrough product, which was later surpassed by a more effective treatment. The root of the problem was not the scientists' inability to create a drug that met its intended biological target, but rather the incorrect choice of the target to begin with. To address this issue, Vertex implemented a strategy of taking away choices and limiting itself to a \"sandbox\" of diseases with validated targets where it believed it had a higher probability of success. This approach required R&D and business development to stay within the same sandbox, and any company initiative that didn't align with this strategy was rejected. This concept may be difficult for leaders to implement, as companies often prefer to say yes to innovation. However, sustainable innovators excel at saying no, focusing their efforts and accelerating innovation. Innovation should not be viewed as an isolated R&D department, but rather as a holistic process involving various parts of an organization. Researchers should work closely with developers, manufacturers, and commercial teams from the earliest stages of innovation. Breaking down internal silos and integrating business development with the same strategy is crucial. Innovation should be measured by how effectively an organization converts its best ideas into products that meet people's needs and create value. Once an innovation succeeds, companies often become complacent and stop innovating to create better medicines for the same disease. However, Vertex's experience with a breakthrough drug that was quickly made obsolete by a competitor drove the organization to continuously strive for \"out-innovating themselves.\" This led to the development of multiple transformative medicines, including treatments for cystic fibrosis and severe Sickle Cell Disease and transfusion-dependent B-thalassemia. Vertex's R&D success rate has exceeded 83% across six diseases, far surpassing the industry average. The key to their success lies in being deliberate about the risks they take.",
  "summary": "More bets don’t necessarily produce more successes",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}